Exploiting the polypharmacology of alectinib for synergistic RNA splicing disruption with RBM39 degraders.
Saved in:
| Title: | Exploiting the polypharmacology of alectinib for synergistic RNA splicing disruption with RBM39 degraders. |
|---|---|
| Authors: | Ma Y; Department of Surgery & Cancer, Imperial College London, London, UK., Poon E; Division of Clinical Studies, The Institute of Cancer Research, London, UK., Jin C; Department of Surgery & Cancer, Imperial College London, London, UK., Martins da Costa B; Division of Clinical Studies, The Institute of Cancer Research, London, UK., Xu Y; Department of Surgery & Cancer, Imperial College London, London, UK., Quazi S; Department of Surgery & Cancer, Imperial College London, London, UK., Zourdoumis N; Department of Surgery & Cancer, Imperial College London, London, UK., Wickremesinghe C; Department of Surgery & Cancer, Imperial College London, London, UK., Chesler L; Division of Clinical Studies, The Institute of Cancer Research, London, UK., Keun HC; Department of Surgery & Cancer, Imperial College London, London, UK. Electronic address: h.keun@imperial.ac.uk., Nijhuis A; Department of Surgery & Cancer, Imperial College London, London, UK. Electronic address: a.nijhuis@imperial.ac.uk. |
| Source: | Cell reports [Cell Rep] 2026 Jan 27; Vol. 45 (1), pp. 116784. Date of Electronic Publication: 2026 Jan 08. |
| Publication Type: | Journal Article |
| Journal Info: | Publisher: Cell Press Country of Publication: United States NLM ID: 101573691 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 2211-1247 (Electronic) NLM ISO Abbreviation: Cell Rep Subsets: MEDLINE |
| Database: | MEDLINE Ultimate |
Be the first to leave a comment!
